Permanent Inactivation of HBV Genomes by CRISPR/Cas9-Mediated Non-cleavage Base Editing

• Main Authors: Yu-Chan Yang (Author), Yu-Hsiang Chen (Author), Jia-Horng Kao (Author), Chi Ching (Author), I-Jung Liu (Author), Chih-Chiang Wang (Author), Cheng-Hsueh Tsai (Author), Fang-Yi Wu (Author), Chun-Jen Liu (Author), Pei-Jer Chen (Author), Ding-Shinn Chen (Author), Hung-Chih Yang (Author)
• Formato: Livro
• Publicado em: Elsevier, 2020-06-01T00:00:00Z.
• Assuntos: article
• Acesso em linha: Connect to this object online.

Current antiviral therapy fails to cure chronic hepatitis B virus (HBV) infection because of persistent covalently closed circular DNA (cccDNA). CRISPR/Cas9-mediated specific cleavage of cccDNA is a potentially curative strategy for chronic hepatitis B (CHB). However, the CRISPR/Cas system inevitabl...